Total Payments
$14,221
2024 Payments
$1,825
Companies
28
Transactions
113
Medicare Patients
3,978
Medicare Billing
$6.8M
Payment Breakdown by Category
Consulting$4,350 (30.6%)
Travel$3,121 (21.9%)
Food & Beverage$2,779 (19.5%)
Other$1,700 (12.0%)
Research$1,527 (10.7%)
Education$745.32 (5.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $4,350 | 3 | 30.6% |
| Travel and Lodging | $3,121 | 8 | 21.9% |
| Food and Beverage | $2,779 | 89 | 19.5% |
| Unspecified | $1,527 | 7 | 10.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500 | 1 | 10.5% |
| Education | $745.32 | 4 | 5.2% |
| Honoraria | $200.00 | 1 | 1.4% |
Payments by Type
General
$12,695
106 transactions
Research
$1,527
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Quidel Corporation | $5,926 | 12 | $0 (2021) |
| PFIZER INC. | $2,170 | 11 | $0 (2024) |
| SANOFI PASTEUR INC. | $1,630 | 12 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,080 | 14 | $0 (2023) |
| Roche Diagnostics Corporation | $1,000 | 1 | $0 (2020) |
| Shire North American Group Inc | $515.85 | 13 | $0 (2019) |
| Talis Biomedical Corporation | $350.00 | 1 | $0 (2022) |
| Horizon Therapeutics plc | $212.40 | 2 | $0 (2022) |
| Welch Allyn | $200.00 | 1 | $0 (2018) |
| Supernus Pharmaceuticals, Inc. | $195.85 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,825 | 12 | SANOFI PASTEUR INC. ($1,527) |
| 2023 | $273.17 | 9 | Corium, LLC ($125.58) |
| 2022 | $518.65 | 7 | Talis Biomedical Corporation ($350.00) |
| 2021 | $297.72 | 11 | Horizon Therapeutics plc ($124.99) |
| 2020 | $3,236 | 11 | Quidel Corporation ($2,100) |
| 2019 | $4,021 | 21 | Quidel Corporation ($3,739) |
| 2018 | $3,552 | 28 | PFIZER INC. ($2,090) |
| 2017 | $497.35 | 14 | Shire North American Group Inc ($203.58) |
All Payment Transactions
113 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/17/2024 | PFIZER INC. | TRUMENBA (Biological), PREVNAR 20, COMIRNATY | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: VACCINES | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Immunology | ||||||
| 08/30/2024 | Janssen Biotech, Inc. | REMICADE (Biological) | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: Immunology | ||||||
| 08/28/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $118.10 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 04/16/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 04/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $70.00 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 04/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $50.00 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 04/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $50.00 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 04/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $50.00 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 04/03/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $636.23 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 04/03/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $530.36 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 04/03/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $140.00 | Research |
| Study: Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | ||||||
| 12/12/2023 | kaleo, Inc. | AUVI-Q (Drug) | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: Allergy | ||||||
| 11/28/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Rare Disease | ||||||
| 11/20/2023 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $50.36 | General |
| Category: PSYCHOLOGY | ||||||
| 09/26/2023 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: VACCINES | ||||||
| 09/26/2023 | SANOFI PASTEUR INC. | MENQUADFI (Biological), BEYFORTUS | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: Vaccines | ||||||
| 07/18/2023 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 06/27/2023 | Merck Sharp & Dohme LLC | ROTATEQ (Biological), VAXNEUVANCE, GARDASIL 9 | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: VACCINE | ||||||
| 06/07/2023 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $110.16 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 03/21/2023 | Merck Sharp & Dohme LLC | ROTATEQ (Biological), VAXNEUVANCE, GARDASIL 9 | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: VACCINE | ||||||
| 09/28/2022 | Talis Biomedical Corporation | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 09/27/2022 | Merck Sharp & Dohme LLC | GARDASIL 9 (Biological), PROQUAD, M-M-R II | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: VACCINE | ||||||
| 09/21/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $87.41 | General |
| Category: UPLIZNA | ||||||
| 09/14/2022 | Sobi, Inc | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL) | SANOFI PASTEUR INC. | $1,527 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,054 | 60,571 | $1.9M | $1.1M |
| 2022 | 12 | 1,049 | 77,399 | $4.7M | $1.7M |
| 2021 | 13 | 1,019 | 86,472 | $5.2M | $2.1M |
| 2020 | 13 | 856 | 80,353 | $4.6M | $1.9M |
Total Patients
3,978
Total Services
304,795
Medicare Billing
$6.8M
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 339 | 34,440 | $1.0M | $629,827 | 61.0% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 16 | 23,700 | $568,800 | $411,186 | 72.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 165 | 529 | $105,800 | $24,452 | 23.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 16 | 81 | $28,350 | $7,593 | 26.8% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 18 | 426 | $63,900 | $6,424 | 10.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 342 | 588 | $44,100 | $5,445 | 12.3% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 122 | 610 | $27,000 | $3,820 | 14.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 142 | $28,400 | $2,898 | 10.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 24 | $3,000 | $990.15 | 33.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 13 | 31 | $1,260 | $235.91 | 18.7% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2022 | 11 | 23,371 | $2.9M | $810,049 | 27.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 306 | 30,420 | $912,600 | $516,261 | 56.6% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 14 | 21,000 | $492,900 | $364,394 | 73.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 182 | 582 | $116,400 | $28,510 | 24.5% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 19 | 475 | $71,250 | $7,487 | 10.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 13 | 72 | $25,200 | $6,956 | 27.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 311 | 543 | $40,725 | $5,245 | 12.9% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2022 | 135 | 671 | $53,680 | $3,458 | 6.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 12 | 138 | $27,600 | $2,971 | 10.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 18 | 44 | $5,500 | $1,679 | 30.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 13 | 42 | $1,470 | $304.11 | 20.7% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2022 | 15 | 41 | $615.00 | $19.73 | 3.2% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2021 | 15 | 25,222 | $2.8M | $928,795 | 33.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 298 | 28,200 | $768,000 | $458,834 | 59.7% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2021 | 15 | 24,600 | $565,800 | $409,517 | 72.4% |
About Dr. Robert Dracker, M.D
Dr. Robert Dracker, M.D is a Blood Banking & Transfusion Medicine healthcare provider based in Liverpool, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528175361.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Dracker, M.D has received a total of $14,221 in payments from pharmaceutical and medical device companies, with $1,825 received in 2024. These payments were reported across 113 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($4,350).
As a Medicare-enrolled provider, Dracker has provided services to 3,978 Medicare beneficiaries, totaling 304,795 services with total Medicare billing of $6.8M. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Blood Banking & Transfusion Medicine
- Other Specialties Pediatrics
- Location Liverpool, NY
- Active Since 08/25/2006
- Last Updated 02/28/2019
- Taxonomy Code 207ZB0001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1528175361
Products in Payments
- Amplivue Lyra Solana Serosep (Device) $3,604
- Sofia2 (Device) $1,500
- POC cobas Liat Analyzer, Assays, Controls and Accessories (Device) $1,000
- V114 (Biological) $986.89
- SOFIA 2 (Device) $600.00
- Otoscope (Device) $200.00
- Azstarys (Drug) $148.78
- CINRYZE (Drug) $128.33
- MYDAYIS (Drug) $127.43
- TREMFYA (Drug) $125.00
- TEPEZZA (Drug) $124.99
- Qelbree (Drug) $118.10
- GATTEX (Drug) $93.09
- UPLIZNA (Drug) $87.41
- Non-Covered Product (Drug) $85.76
- Solana (Device) $85.75
- ELAPRASE (Biological) $79.95
- QELBREE (Drug) $77.75
- Sofia (Device) $65.81
- BEXSERO (Biological) $64.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.